Noval Oral Anticoagulants: Life Is Not As Simple as Anticipated
|
|
- Brandon Adrian McBride
- 6 years ago
- Views:
Transcription
1 Noval Oral Anticoagulants: Life Is Not As Simple as Anticipated PRESENTED BY VICKI L GROO, PHARMD CLINICAL ASSOCIATE PROFESSOR DEPARTMENTS OF PHARMACY PRACTICE AND CARDIOLOGY UNIVERSITY OF ILLINOIS AT CHICAGO
2 NOACs DOACs Provider Patient
3 Objectives: Review dosing for atrial fibrillation and venous thromboembolism Provide guidance on when to hold NOACs for procedures Review options for reversal Discuss what is on the horizon for new indications and dosing
4 NOAC Dosing
5 NOAC Dosing Renal Impairment: Afib: Renal or patient characteristic dose adjustments Some based on PK modeling only (ie no clinical data) VTE: varies by drug, check prescribing guide Contraindicated for CrCl < 30 ml/min vs renal dose adjustment vs no adjustment Drug interactions PgP inhibitors: Increase exposure (dabigatran and edoxaban) Strong CYP3A4 + PgP inhibitors: Increase exposure (apixaban and rivaroxaban) PgP inducers or PgP + CYP3A4 inducers: Decrease exposure CONTRAINDICATED ALL VTE initial treatment varies Duration LMWH vs oral load
6 NOAC Dosing: Apixaban (Eliquis) XA inhibitor with combined renal (30%) and liver elimination Start when INR < 2.0 if switching from warfarin Use parenteral agent until INR therapeutic if switching to warfarin No Dose adjustments on CrCl alone Non-valvular Afib DVT/PE Most patients 5 mg bid When 2 characteristics present Age 80; Wt 60 kg; SrCr mg bid ESRD on HD If Age 80 OR Wt 60 kg 5 mg bid* 2.5 mg bid* Initial Dose mg bid x 7 days* Maintenance Dose mg bid* Extended Rx to prevent recurrence mg bid* * Based on PK modeling for ESRD on HD
7 NOAC Dosing: Dabigatran (Pradaxa) Direct thrombin inhibitor with 80% renal elimination Dialyzable Start when INR < 2.0 if switching from warfarin If switching to warfarin, overlap with warfarin as follows: CrCl > 50 x 3 days / Cr Cl x 2 days / Cr Cl x 1 day Store original bottle / swallow whole Non-Valvular Afib DVT/PE^ CrCl > 30 ml/min 150 mg bid 150 mg bid Maintenance dose and to reduce risk of recurrence CrCl ml/min 75 mg bid * contraindicated CrCl < 15 ml/min contraindicated contraindicated ^ Treat 1 st with LMWH or UFH x 5-10 days * Based on PK modeling for CrCl
8 NOAC Dosing: Edoxaban (Savaysa) XA inhibitor with 50% renal elimination Start when INR < 2.5 if switching from warfarin If switching to warfarin; reduce dose by 50% then d/c when INR therapeutic or Use parenteral agent until INR therapeutic Non-Valvular Afib DVT/PE^ CrCl > 95 ml/min Contraindicated 60 mg daily CrCl > ml/min 60 mg daily 60 mg daily CrCl ml/min 30 mg daily* 30 mg daily* CrCl < 15 ml/min contraindicated contraindicated Any CrCl with weight 60 kg mg daily ^ Treat 1 st with LMWH or UFH x 5-10 days * Based on PK modeling for CrCl
9 NOAC Dosing: Rivaroxaban (Xarelto) XA inhibitor with combined renal (66%) and liver elimination Start when INR < 3.0 if switching from warfarin Use parenteral agent until INR therapeutic if switching to warfarin Take with food (usually pm meal) Non-valvular Afib DVT/PE Initial Dose mg bid x 21 days Maintenance Dose 20 mg daily 20 mg daily CrCl < 50 ml/min including ESRD on HD 15 mg daily* Extended Rx to prevent recurrence mg daily Contraindicated CrCl < 30 ml/min * Based on PK modeling for CrCl or ESRD on HD
10 NOAC Dosing: The need to get it right NOAC dosing patterns and associated outcomes in patients with Afib and renal impairment 14,865 patients from Optum Data Warehouse (Medicare Advantage enrollees) Started apixaban, dabigatran or rivaroxaban from 10/1/2010 to 9/30/2015 Creatinine available before treatment initiation Outcomes: Ischemic stroke or systemic embolism and major bleeding egfr calculated using CKD-EPI (Sr Cr, age, gender, race) Apixaban if SrCr > 1.5 (sensitivity analysis performed for age > 80) Propensity score matching used to balance baseline characteristics b/t reduced and standard dose patients Yao X, Shah ND, Sangaralingham LR, et al. J Am Coll Cardiol 2017;69:
11 NOAC Dosing: The need to get it right 1473 with indication for dose reduction 79 years GFR 39, CHADSVASc =5 HAS-BLED= 4 43% received standard dose OVERDOSE Apixaban 5x risk of stroke 13,392 no indication for dose reduction 70 years, GFR 73 CHADSVASc = 4 HAS-BLED = % received reduced dose UNDERDOSED Stroke/ 100 pt yrs 2.32S vs 1.85R P=0.48 Bleed/ 100 pt yrs 11.29S vs 5.06R P=0.03 Stroke/ 100 pt yrs 1.43S vs 1.70R P=NS Bleed/ 100 pt yrs 5.03S vs 5.43R P=NS Yao X, Shah ND, Sangaralingham LR, et al. J Am Coll Cardiol 2017;69: , Nielsen PB, Skjoth F, Sogaard M, et al. BMJ 2017;356 doi:
12 Surgical Interruption
13 Surgical Interruption: Estimate thromboembolic risk: Applies to evaluation need for bridging Risk Stratum A Fib VTE Very High CHADSVASC score 6 CVA or TIA within 3 months Rheumatic valvular disease VTE within 3 months Severe thrombophilia* High CHADSVASC score of 4-5 VTE in past 3-12 months Non-severe thrombophilia^ Recurrent VTE Active cancer Moderate CHADSVASC score of 2-3 VTE > 12 months and not other risk factors * Protein C or S deficiency, antithrombin or antiphospholipid antibodies ^ heterozygous factor V Leidein or prothrombin gene mutation Bridging is NOT recommended during therapeutic interruption for NOACs Douketis JD, Spyropoulos AC, Spencer FA, et al. Chest 2012; 141(2 Suppl):e326S, Doherty JU, Gluckman TJ, Hucker WJ, et al. J Am Coll Cardiol 2017;69:
14 Surgical Interruption PATIENT BLEED RISK FACTORS HAS-BLED parameters Hypertension SPB > 160mmHg Abnormal renal function dialysis/transplant or Cr > 2.6 Abnormal liver function (cirrhosis, ALT/AST > 3x ULN or bili > 2x ULN) Prior Stroke Bleeding Hx of anemia or predisposition Labile INR (VKA) Elderly > 65 years Antiplatelet or NSAID use Drug or alcohol use > 8 drinks/week Other ICH or other bleed in last 3 months Bleed history with similar procedure Quantitative or qualitative platelet abnormality uremia Bleed history from previous bridging HAS-BLED Scoring 1 point each Score 3 predictive of bleeding events during bridging Doherty JU, Gluckman TJ, Hucker WJ, et al. J Am Coll Cardiol 2017;69: Omran H, Bauersachs R, Rubenacker S, et al. Thromb Haemost 2012;108:65-73
15 Surgical Interruption: Surgical Risk Evaluation Minimal Bleeding Risk Minor dermatologic procedures (e.g. excision of basal and squamous skin cancers, actinic keratosis, and premalignant or cancerous skin nevi) Cataract procedures Dental cleanings, fillings Low Bleeding Risk 2 day risk of major bleed < 2% Minor dental procedures (simple dental extractions, restorations, prosthetics, endotonics) Cutaneous/lymph node biopsies Shoulder/foot/hand surgery Coronary angiography EP procedures: ICD implant/ ablations GI scope +/- biopsy Abdominal hysterectomy Hemorrhoidal surgery Bronchoscopy +/- biopsy Epidural injections with INR < 1.2 Pacemaker battery change Arthroscopy High Bleeding Risk 2 day risk of major bleed 2% Cancer surgery Major orthopedic surgery Reconstructive plastic surgery TURP, blader resection or tumor ablation Nephrectomy, kidney biopsy Colonic polyp resection Bowel resection PEG placement or ERCP Cardiac, intracranial, or spinal surgery Surgery in high vascular organs Any major operation > 45 min Doherty JU, Gluckman TJ, Hucker WJ, et al. J Am Coll Cardiol 2017;69: Online Appendix for complete list
16 Surgical Interruption Check Creatinine Clearance!!! UIC guide is up to 3 days Doherty JU, Gluckman TJ, Hucker WJ, et al. J Am Coll Cardiol 2017;69:
17 Surgical Interruption Resume NOAC 1 day after low bleeding risk procedures 2-3 days after high bleeding risk procedures AND Adequate hemostasis is achieved
18 Doherty JU, Gluckman TJ, Hucker WJ, et al. J Am Coll Cardiol 2017;69: Narouze S, Benzon HT, Provenzano DA, et al. Reg Anesth Pain Med 2015;40: Surgical Interruption: Other Considerations Post procedural VTE prophylaxis with AC not needed: Patient is fully anticoagulated Can still consider pneumatic compression if appropriate Can consider prophylactic doses of NOAC, LMWH, or UFH 6-8 hours post procedure until appropriate to increase to full treatment dose. Apixaban 2.5 mg bid Dabigatran 150 mg daily Edoxaban mg daily Rivaroxaban 10 mg daily Neuraxial Anesthesia All have black box warning risk of spinal or epidural hematoma Each PI provides guidance American Society of Regional Anesthesia and Pain Management wait 24 hours after catheter removal
19 Surgical Interruption Doherty JU, Gluckman TJ, Hucker WJ, et al. J Am Coll Cardiol 2017;69:
20 Reversal
21 Reversal No reversal agents available during landmark clinical trials Management and Outcomes of Major Bleeding: Dabigatran vs Warfarin 27,419 patients treated for 6-36 months in 5 phase III trials 1034 patients (627 dabigatran and 407 warfarin) had 1121 major bleeds Dabigatran patients were older, had lower CrCl, and more often used aspirin or NSAIDS 30 day mortality favors dabigatran (9.1% vs 13%, p=0.057) OR after adjustment 0.66 ( p=0.051) ICU stay favors dabigatran (1.6 vs 2.7 nights, p = 0.01) Dabigatran more likely to receive blood transfusion / warfarin received plasma Who should reversal be considered in? Emergent need for surgery or invasive procedure (4-6 hours) and/or Major bleeding while on antithrombotic therapy Majeed A, Hwang HG, Connoly SF, et al. Circulation 2013;128:
22 NOAC Reversal Agents Agent Idarucizumab Andexanet Alfa Ciraparantag Target Dabigatran only Factor Xa inhibitors* UFH, Factor XA inhibitors, Dabigatran Mechanism Humanized antibody fragment; binds dabigatran with 350x the affinity of thrombin Recombinant modified human factor Xa decoy protein; directly binds target and restores activity of factor Xa Small synthetic molecule; directly binds drug target to block binding to target site Onset < 10 minutes 2 5 minutes 5 20 minutes FDA Approval FDA 2015 Currently delayed by FDA until more data FDA granted fast track review in April 2015 with edoxaban and enoxaparin Currently in Phase 3 studies Administration Data 5 gm total given as 2 consecutive IV bolus or infusion (2.5 gm each) 90 pts (ICH, GI, trauma) / procedure clotting times normalized 88-98% 33/36 normal procedure hemostasis 11.4 hrs to hemostasis in bleeds Dose based on drug and timing of last dose; IV bolus + 2 hour infusion Healthy subjects: AntiXA activity 92-94% ANNEXA 4 ongoing: 67 pts bleeding (GI and ICH) Excellent/good hemostasis 79% IV bolus; future studies may include infusion Healthy volunteer studies with edoxaban and enoxaparin; reverses effect on whole blood clotting time Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015;373: Siegal DM Curnutte JT, Connolly SJ, et al. N Engl J Med 2015;373: Connoly SJ, Milling TJ, Eikelboom JW, et al. N Engl J Med 2016;375: ,Milling TJ, Kaatz S. Am J Emerg Med 2016;34:39-45
23 NOAC Reversal Agents Agent Idarucizumab Andexanet Alfa Ciraparantag Target Dabigatran only Factor Xa inhibitors* UFH, Factor XA inhibitors, Dabigatran Mechanism Humanized antibody fragment; binds dabigatran with 350x the affinity of thrombin Recombinant modified human factor Xa decoy protein; directly binds target and restores activity of factor Xa Small synthetic molecule; directly binds drug target to block binding to target site Onset < 10 minutes 2 5 minutes 5 20 minutes FDA Approval FDA 2015 Currently delayed by FDA until more data FDA granted fast track review in April 2015 with edoxaban and enoxaparin Currently in Phase 3 studies Administration Data 5 gm total given as 2 consecutive IV bolus or infusion (2.5 gm each) 51 bleeding pts (ICH, GI, trauma) 39 urgent procedures clotting times normalized 88-98% 33/36 normal procedure hemostasis 11.4 hrs to hemostasis in bleeds Dose based on drug and timing of last dose; IV bolus + 2 hour infusion Healthy subjects: AntiXA activity 92-94% ANNEXA 4 ongoing: 67 pts reported Excellent/good hemostasis 79% IV bolus; future studies may include infusion Healthy volunteer studies with edoxaban and enoxaparin; reverses effect on whole blood clotting time Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015;373: Siegal DM Curnutte JT, Connolly SJ, et al. N Engl J Med 2015;373: Connoly SJ, Milling TJ, Eikelboom JW, et al. N Engl J Med 2016;375: ,Milling TJ, Kaatz S. Am J Emerg Med 2016;34:39-45
24 NOAC Reversal: PCCs Use for XA inhibitors 3-factor PCC: (II, IX, X) 50 U/kg IV, may repeat q 12 hours 4-factor PCC: (II, VII IX, X, Protein C and S) 50 U/kg x 1 FEIBA has activated factor VII? Thromboembolic risk KCentra all inactivated factors Dose not based on INR!!! What do we know? Animal models of bleeding; decreased blood loss Healthy subjects; reverses abnormal coagulation values, decreases bleeding, improves hemostasis ICH; 18 pts suggested reduces hemorrhagic complications and hematoma expansion Eikelboom, Merli G. Am J Emerg Med 2016;34:3-8, Nutescu EA, Dager WE, Kalus JS, et al. Am J Health-Syst Pharm 2013;70:e82-97
25 NOAC Reversal Summary XA Inhibitor PCC Major Bleeding or Urgent invasive procedure Dabigatran Idarucizumab Other Considerations: Time of last dose and half-life of drug Dabigatran hours, increases with declining renal fxn Apixaban 8-15 hours Edoxaban hours Rivaroxaban 5-9 hours, increases to hours in elderly Activated charcoal for overdose Dialysis for dabigatran Prevent Bleeding Patient selection Correct Dose Antiplatelet NSAIDs
26 What s New
27 COMPASS 27,395 patients with stable ASCVD Rivaroxaban 2.5 mg bid + ASA 100 mg daily Rivaroxaban 5 mg bid + placebo ASA 100 mg daily + placebo Primary outcome: CV death, stroke or MI Key Inclusion/Exclusion Age < 65 had to have ASCVD in 2 vascular beds or 2 additional risk factors (smoking, DM, egfr < 60 ml/min, heart failure, nonlacunar ischemic stroke > 1 month egfr < 15 ml/min, severe HF, high bleeding risk, DAPT, anticoagulation Population: 68 years, male, 62% white on ACEi or ARB, beta-blocker and lipid lowering agent Outcomes: rivaroxaban 2.5 mg bid + ASA (4.9%) vs ASA (5.4%) HR 0.76, p<0.001 Increased risk of major bleeding with combination: 3.1 vs 1.9%, HR 1.70, p>0.001 Net clinical benefit (1 outcome + fatal/critical organ bleeding) favors combination: 4.7 vs 5.9%, HR 0.8, p<0.001 Eikelboom JW, Connolly SJ, Bosch J, et al. N Engl J Med 2017;377:
28 PIONEER 2124 patients with atrial fibrillation in need of PCI with stent Rivaroxaban 15 mg once daily (10 mg if CrCl ml/min) + P2Y12 inhibitor x 12 months Rivaroxaban 2.5 mg bid + DAPT x 1, 6, or 12 months After 1 or 6 months of triple therapy completed, dose change to mg daily + ASA until 12 months Dose adjusted VKA + DAPT x 1, 6, or 12 months Duration of DAPT specified by investigator prior to randomization Primary outcome: clinical significant bleeding Key exclusion: CrCl < 30 ml/min, Hx of CVA/TIA or GI bleed in last 12 months, Hgb < 10 g/dl Population: 70 years, white, CrCL ml/min (28% < 60 ml/min), clopidogrel, DES 66% Outcomes: Both rivaroxaban groups had lower rates of bleeding than warfarin (HR 0.59 and 0.63, p<0.001) No difference in MACE (HR 1.08, p 0.75 and HR 0.93, p 0.76) Gibson CM, Mehran R, Bode C, et al. N Engl J Med 2016;375:
29 EINSTEIN CHOICE 3365 patients with VTE randomized after 6-12 months of treatment Rivaroxaban 20 mg daily Rivaroxaban 10 mg daily ASA 100 mg daily Primary outcome: symptomatic recurrent VTE Key Inclusion/Exclusion Initial treatment could have been any AC, no more than 7 days interruption prior to randomization CrCl < 30 ml/min or hepatic disease associated with coagulopathy Population: 58 yo, 55% male, 60% provoked, 20% prior VTE Outcomes: rivaroxaban 20 mg (1.5%), 10 mg (1.2%), ASA (4.4%); HR 0.34 and 0.26, p<0.001 Major bleeding: rivaroxaban 20 mg (0.5%), 10 mg (0.4%), ASA 0.3%); HR 1.64, p=0.50 Weitz, JI, Lensing AWA, Prins MH, et al. N Engl J Med 2017;376:
30 Final Thoughts: NOACS SIMPLE Dosing Dosing varies by indication Pay attention to renal function and drug interactions New indications or doses on the horizon (2.5 mg dose of rivaroxaban not currently available) Surgical interruption Based on risk and drug half-life Parenteral bridging is not necessary Bleeding Idaruzimab for dabigatran PCC for XA New agents on the horizon Refer to prescribing guides as needed Create institutional clinical care guidelines and reference documents
Update on Oral Anticoagulants. Dr. Miten R. Patel Cancer Specialists of North Florida Cell
Update on Oral Anticoagulants Dr. Miten R. Patel Cancer Specialists of North Florida Cell 904-451-9820 Email miten.patel@csnf.us Overview Highlights of the 4 new approved oral anticoagulants Results from
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationUpdate on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA
Update on the NOAC s: 2018 Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular Center UC San Diego The NOACS, chronologically Dabigatran:
More informationUpdates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism
Disclosures Updates in Anticoagulation for Atrial Fibrillation and Venous Thromboembolism No financial conflicts of interest Member of the ABIM Focused- Practice in Hospital Medicine Self Examination Process
More informationDirect Oral Anticoagulants
Direct Oral Anticoagulants Holly Jahn, PharmD, CACP Objectives Identify the FDA approved indications for use, appropriate dosing, and monitoring parameters for each direct oral anticoagulant. Distinguish
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationThe INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center
The INR: No Need Anymore? Daniel Blanchard, MD Professor of Medicine Director, Cardiology Fellowship Program UCSD Sulpizio Cardiovascular Center What is the INR? Tissue Factor (Factor III) is added to
More informationChallenging Anticoagulation Case Studies. Earl J. Hope, M.D. Tower Health Cardiology
Challenging Anticoagulation Case Studies Earl J. Hope, M.D. Tower Health Cardiology Financial Disclosures Nothing to disclose Objectives: 1. Understand indications for heparin bridging. 2. Recognize the
More informationReversal Agents for Anticoagulants Understanding the Options. Katisha Vance, MD, FACP Alabama Oncology January 28, 2017
Reversal Agents for Anticoagulants Understanding the Options Katisha Vance, MD, FACP Alabama Oncology January 28, 2017 Objectives Appropriately recommend reversal agents for Vitamin K antagonists Appropriately
More informationProfessional Practice Minutes December 7, 2016
Professional Practice Minutes December 7, 2016 **New Opportunity for Patient Education** We can now request the educational videos we want our patients to watch after our visit. Video topics include colon
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More information3/25/2016. Objectives for Pharmacists. Stop the Bleeding! New Reversal Agents. Objectives for Pharmacy Technicians. Assessment Pre-test
Objectives for Pharmacists Stop the Bleeding! New Reversal Agents Gary D Peksa, Pharm.D., BCPS Clinical Pharmacy Specialist, Emergency Medicine Rush University Medical Center Review current strategies
More informationNew Oral Anticoagulants
New Oral Anticoagulants Tracy Minichiello, MD Associate Professor of Medicine Chief, San FranciscoVA Anticoagulation and Thrombosis Services What percentage of time do patients on warfarin spend in therapeutic
More informationPerioperative Anticoagulation Management
Perioperative Anticoagulation Management ACP Delaware Chapter Scientific Meeting Feb 9, 2019 Andrew Dunn, MD, MPH, MACP Chief, Division of Hospital Medicine Mount Sinai Health System, NY DISCLOSURES Desai
More informationReversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016
Reversal of Novel Oral Anticoagulants Angelina The, MD March 22, 2016 Argatroban Bivalirudin Enoxaparin Lepirudin Heparin Dabigatran Apixaban 1939 1954 1998 2000 1999 2001 10/2010 7/2011 12/2012 1/2015
More informationAnticoagulation Task Force
Anticoagulation Task Force Newest Recommendations Donald Zabriskie, BPharm, MBA, RPh Pharmacy Patient Care Services Cleveland Clinic- Fairview Hospital THE DRUGS THE PERFECT ANTICOAGULANT Oral administration
More informationNOACs in AF. Dr Colin Edwards Auckland Heart Group and Waitemata DHB. Dr Fiona Stewart Auckland Heart Group and Auckland DHB
NOACs in AF Dr Colin Edwards Auckland Heart Group and Waitemata DHB Dr Fiona Stewart Auckland Heart Group and Auckland DHB Conflict of Interest Dr Fiona Stewart received funding from Pfizer to attend the
More informationANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY
ANTICOAGULATION: THE DO'S AND DON'TS OF BRIDGE THERAPY SATURDAY/11:30AM-12:30PM ACPE UAN: 0107-9999-17-236-L01-P 0.1 CEU/1.0 hr Activity Type: Application-Based Learning Objectives for Pharmacists: Upon
More informationManaging Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants
Managing Hemorrhagic Complications of Non-Vitamin K Antagonist Oral Anticoagulants MICHAEL E. MULLINS MD FAACT FACEP Washington University School Of Medicine Chair, BJH Anticoagulation Subcommittee Chair,
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More information3/19/2012. What is the indication for anticoagulation? Has the patient previously been on warfarin? If so, what % of the time was the INR therapeutic?
Abigail E. Miller, PharmD, BCPS Clinical Specialist, Cardiology University of North Carolina Hospitals I have no personal financial relationships with the manufacturers of the products to disclose. Boehringer
More informationIntroduction. Blood Pressure
Introduction Spontaneous intracerebral hemorrhage (ICH) is a major cause of morbidity and mortality worldwide [1]. Of a number of factors that have been linked to ICH (e.g., higher rates in Asians and
More informationNew Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY
New Oral Anticoagulants in treatment of VTE, PE DR.AMR HANAFY (LECTURER OF CARDIOLOGY ) ASWAN UNIVERSITY Fact VTE is deadly! It nibbles after it bites! The 30-day mortality rates for first-time DVT or
More informationPerioperative Management of Anticoagulation
Perioperative Management of Anticoagulation Presented By: Nibal R. Chamoun, PharmD, BCPS Clinical Assistant Professor, Clinical Coordinator Lebanese American University, School of Pharmacy Presented at:
More informationPractical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease
Practical Considerations for Using Oral Anticoagulants in Patients with Chronic Kidney Disease Cyrille K. Cornelio, Pharm.D. PGY2 Cardiology Pharmacy Resident The University of Oklahoma College of Pharmacy
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationLet s Gi e The So ethi g To Clot About: Controversies in Anticoagulation
Let s Gi e The So ethi g To Clot About: Controversies in Anticoagulation Janna Beavers, MS, PharmD, BCPS Cardiology Clinical Pharmacy Specialist WakeMed Health & Hospitals Raleigh, NC March 13, 2018 Pharmacist
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationUpdates in Coagulation Thrombophilia testing and direct oral anticoagulants. Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017
Updates in Coagulation Thrombophilia testing and direct oral anticoagulants Kevin Y. Chen, MD Hematology and Medical Oncology October 13, 2017 No conflicts of interest Introduction to thrombosis Hemostasis
More informationPeri-Procedural Management of Antithrombotic Agents
u Peri-Procedural Management of Antithrombotic Agents An Integrated Care Pathway of the Collaborative Care Network Subject Matter Experts: Will Maxted, MD Veronica Kerner, PharmD Pathway Custodian: Pat
More informationLatest News and Clinical Applications of NOACs: What about Antidotes?
Optimizing outcomes in Atrial Fibrillation Latest News and Clinical Applications of NOACs: What about Antidotes? McMaster Cardiology Update September 11, 2015 Agenda Real world data on the use of NOACs
More informationChallenges in Coagulation
Challenges in Coagulation Michael H. Rosove, MD Clinical Professor of Medicine UCLA Division of Hematology-Oncology April 30, 2016 Vitamin K Deficiency Vitamin K1 source from diet Vitamin K2 source from
More informationKCS Congress: Impact through collaboration
Stroke Prevention in Atrial Fibrillation (SPAF) in Kenya Elijah N. Ogola FACC University of Nairobi Kenya Cardiac Society Annual Scientific Congress Mombasa 28 th June 1 st July 2017 KCS Congress: Impact
More information2017 Bryan Health Primary Care Conference. Dale Hansen MD Bryan Heart 5/20/17
2017 Bryan Health Primary Care Conference Dale Hansen MD Bryan Heart 5/20/17 I have no financial disclosures or conflicts of interest Bridging Anticoagulation Primum Non Nocere 67 y.o. male with mechanical
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationIschemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants
Ischemic and hemorrhagic strokes in the context of the direct acting oral anticoagulants Van Hellerslia, PharmD, BCPS, CACP Clinical Assistant Professor Temple University School of Pharmacy Over 4 million
More informationNOACS/DOACS*: PERI-OPERATIVE MANAGEMENT
NOACS/DOACS*: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide guidance for the peri-operative management of patients who are receiving a newer direct oral anticoagulant (DOAC) and require an elective surgery/procedure.
More informationThe DOACs. Update on Anticoagulation 10/20/2017. Dabigatran (Pradaxa ) Rivaroxaban (Xarelto ) Apixaban (Eliquis ) Edoxaban (Savaysa ) Objectives
Objectives Update on Anticoagulation JEFF REIST PHARMD, BCPS CLINICAL ASSOCIATE PROFESSOR UNIVERSITY OF IOWA COLLEGE OF PHARMACY At the conclusion of this program, the participant should be able to: List
More informationAppendix IV - Prescribing Guidance for Apixaban
Appendix IV - Prescribing Guidance for Apixaban Patient Factors Dose of Apixaban If your patient has any of the following MAJOR risk factors: Hypersensitivity to the active substance or to any of the excipients
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationReversal Agents for NOACs (Novel Oral Anticoagulants)
Reversal Agents for NOACs (Novel Oral Anticoagulants) Current status and future challenges Paul A Reilly, PhD Clinical Research, Boehringer Ingelheim, Inc CSRC Symposium Washington DC Oct 18, 2016 Atrial
More informationDirect Oral Anticoagulant Reversal
08 June 2018 No. 08 Direct Oral Anticoagulant Reversal M Khattab Moderator: E Hodgson School of Clinical Medicine Discipline of Anaesthesiology and Critical Care CONTENTS INTRODUCTION... 3 Pharmacokinetics
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationDo s and Don t of DOACs DISCLOSURE
Do s and Don t of DOACs Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau - None Consultant/Research none Content Expert: Elsevier
More informationTim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio
Tim Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy, Akron General Medical Center for Family Medicine Professor, Northeast Ohio Medical University Objectives 1. 2. 3. 4. Review and discuss
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationSpontaneous Atrial Fibrillation and Noacs and Reversal agents
Spontaneous Atrial Fibrillation and Noacs and Reversal agents Laurent Lewkowiez, MD Regional Service Chief, Hospital Cardiology CPMG Cardiac Electrophysiology Educational Goals relationship between atrial
More informationNew and old anticoagulants. Anticoagulation Focus on Direct Oral Anticoagulants
Anticoagulation Focus on Direct Oral Anticoagulants Tzu-Fei Wang, MD Assistant Professor Department of Internal Medicine Division of Hematology The Ohio State University Wexner Medical Center Objectives
More informationNibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator
Nibal R. Chamoun, Pharm.D., BCPS Clinical Assistant Professor of Pharmacy Practice at the Lebanese American University Clinical Pharmacy Coordinator at LAUMCRH Review the mechanism of action, indications
More information10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI
10 Key Things the Vascular Community Should Know about the DOACs Heather Gornik, MD, RVT, RPVI Cleveland Clinic Heart and Vascular Institute Heather L. Gornik, MD has the following relationships to disclose:
More informationWarfarin for Long-Term Anticoagulation. Disadvantages of Warfarin. Narrow Therapeutic Window. Warfarin vs. NOACs. Challenges Monitoring Warfarin
1 2:15 pm The Era of : Selecting the Best Approach to Treatment SPEAKER Gregory Piazza, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Gregory Piazza,
More information6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia
6 th ACC-SHA Joint Meeting Jeddah, Saudi Arabia October 31 st - November 1 st, 2015 NOACS vs. Coumadin in Atrial Fibrillation: Is It Worth to Switch? Raed Sweidan, MD, FACC Consultant and Head of Cardiac
More informationNovel Oral An,coagulants: Prac,cal Aspects. Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015
Novel Oral An,coagulants: Prac,cal Aspects Caroline Berube, MD Clinical Associate Professor Division of Hematology November 2015 The New Oral An,coagulants (NOACs) The Non VKA Oral An,coagulants (NOACs)
More informationDEEP VEIN THROMBOSIS (DVT): TREATMENT
DEEP VEIN THROMBOSIS (DVT): TREATMENT OBJECTIVE: To provide an evidence-based approach to treatment of patients presenting with deep vein thrombosis (DVT). BACKGROUND: An estimated 45,000 patients in Canada
More informationManaging Perioperative Anticoagulation. Edie Shen MD
Managing Perioperative Anticoagulation Edie Shen MD Anticoagulation VKA Warfarin (Coumadin) DOACs Direct Thrombin Inhibitor Dabigatran (Pradaxa) Factor Xa Inhibitor Rivaroxaban(Xarelto) Apixaban(Eliquis)
More informationUPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS
UPDATE ON TREATMENT OF ACUTE VENOUS THROMBOSIS Armando Mansilha MD, PhD, FEBVS 16 th National Congress of the Italian Society of Vascular and Endovascular Surgery Bologna, 2017 Disclosure I have the following
More informationDOAC for VTE. Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University
DOAC for VTE Direct Oral Anticoagulants Clint Shedd DNP, FNP-BC Emory University No disclosures Direct Oral Anticoagulants Understand VTE and the ACCP s position on it List the DOACs available in the US
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationContent 1. Relevance 2. Principles 3. Manangement
Intracranial haemorrhage and anticoagulation Department of Neurology,, Germany Department of Neurology, Heidelberg University Hospital, Germany Department of Clinical Medicine Copenhagen University, Denmark
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationBridging anticoagulation definition
Bridging anticoagulation definition Giving a short-acting anticoagulant, consisting of sc LMWH or ev UFH for 10 to 12 day period during interruption of VKA therapy when the INR is not within therapeutic
More informationAnticoagulants: Agents, Pharmacology and Reversal
Anticoagulants: Agents, Pharmacology and Reversal Lori B Heller, M.D. Cardiac Anesthesiology Swedish Heart and Vascular Institute Medical Director, Swedish Blood Management Clinical Instructor, University
More informationIdarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):
Idarucizumab for Dabigatran Reversal Pollack CV, Reilly PA, Eikelboom J, et al. N Engl J Med 2015; 373(6):511-520. Objective: To measure the safety of idarucizumab to reverse dabigatran anticoagulant effects
More informationThey re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants)
They re Not So New Anymore Update on NOAC s (Novel Oral Anticoagulants) Daniel B. DiCola, MD Paul W. Ament, PharmD Daniel DiCola, MD ddicola@excelahealth.org Faculty: Latrobe Area Hospital, Excela Health
More informationNOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations
NOACs for Primary and Secondary Stroke Prevention: From Clinical Trials to Real-World Data To Practical Considerations Mark J. Alberts, MD, FAHA Hartford HealthCare Hartford, CT USA AF confers an increased
More informationBLOOD DISEASE RESEARCH FOUNDATION
BLOOD DISEASE RESEARCH FOUNDATION BLOOD DISEASE RESEARCH FOUNDATION The mission of Blood Disease Research Foundation is to support hematological research, e.g. by donating grants for thesis work and abstract
More informationManaging Bleeding in the Patient on DOACs
Managing Bleeding in the Patient on DOACs Spring 2016 Jean M. Connors, MD Anticoagulation Management Services BWH/DFCI Hemostatic Antithrombotic Stewardship BWH Assistant Professor of Medicine, HMS Conflicts
More informationA Brief History of the World of Anticoagulation
A Brief History of the World of Anticoagulation Allison Burnett, PharmD, CACP, PhC Clinical Assistant Professor- UNM College of Rx Antithrombosis Stewardship Pharmacist University of New Mexico Hospital
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationComparison of novel oral anticoagulants (NOACs)
Comparison of novel oral anticoagulants (NOACs) For guidance for full information refer to individual SPCs available at www.medicines.org.uk Licensed indications for NOACs Prevention of stroke and systemic
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationThe Age of the Novel Anticoagulants. Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology
The Age of the Novel Anticoagulants Peter Netzler, MD April 21, 2017 Carolina Cardiology Electrophysiology Disclosures Speaker bureau for the Bristol-Myers Squibb and Pfizer alliance for Eliquis Direct
More informationA Cascade of Updates: Hot Topics in Anticoagulation
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationOral Anticoagulation Drug Class Prior Authorization Protocol
Oral Anticoagulation Drug Class Prior Authorization Protocol Line of Business: Medicaid P & T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationNovel Anticoagulants: Emerging Evidence
18/10/2016 Topics: Novel Anticoagulants: Emerging Evidence Dr Matthew Swale Electrophysiologist Genesis Care NOAC Novel Oral Anti Coagulant Now Non-Vit K Oral Anti Coagulant DOAC Direct Oral Anti Coagulant
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationDisclosure Slide. Controversies in Anticoagulation. Presenter Disclosure Information. Challenges in Anticoagulation
1:15 2:15 PM Challenges in Anticoagulation SPEAKER Nasser Lakkis, MD, FACC, FSCAI Presenter Disclosure Information The following relationships exist related to this presentation: Nasser Lakkis, MD, FACC,
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationDIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING
DIRECT ORAL ANTICOAGULANTS: WHEN TO USE, WHICH TO CHOOSE AND MANAGEMENT OF BLEEDING KATHERINE STIRLING CONSULTANT PHARMACIST ANTICOAGULATION AND THROMBOSIS DR LISHEL HORN CONSULTANT HAEMATOLOGIST HAEMOSTASIS
More informationEndoscopy and the Anticoagulated Patient
Endoscopy and the Anticoagulated Patient John R. Saltzman MD, FACG Director of Endoscopy Brigham and Women s Hospital Professor of Medicine Harvard Medical School Objectives To accurately assess the risk
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationDisclosure and Conflict of Interest
A Cascade of Updates: Hot Topics in Anticoagulation Heather A. Powell, PharmD, BCPS Assistant Professor of Clinical Sciences Roosevelt University College of Pharmacy Golden L. Peters, PharmD, BCPS Associate
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationDirect Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT
Direct Oral Anticoagulants (DOACs). Dr GM Benson Director NI Haemophilia Comprehensive Care Centre and Thrombosis Unit BHSCT OAC WARFARIN Gold standard DABIGATRAN RIVAROXABAN APIXABAN EDOXABAN BETRIXABAN
More informationNew Oral Anticoagulants in Everyday Practice: Addressing Common Clinical Scenarios and Questions not covered by the big trials
New Oral Anticoagulants in Everyday Practice: Addressing Common Clinical Scenarios and Questions not covered by the big trials James Douketis, MD, FRCPC Specialty: Internal Medicine Professor, Department
More informationPerioperative Management of Novel Oral Anticoagulants (NOACs) Hardy Shah PharmD NEANA March 2017
Perioperative Management of Novel Oral Anticoagulants (NOACs) Hardy Shah PharmD NEANA March 2017 Disclosures Presenter has no actual or potential conflicts of interest in relation to this program Question
More informationReversal of direct oral anticoagulants in the patient with GI bleeding. Marc Carrier
Reversal of direct oral anticoagulants in the patient with GI bleeding Marc Carrier Disclosure Faculty: Dr. Marc Carrier Relationships with commercial interests: Grants/Research Support: Leo Pharma, Bristol
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationAdvances in Anticoagulation
May 18, 2017 Advances in Anticoagulation Wei Ling Lau, MD Assistant Professor, Nephrology University of California, Irvine Talk Outline High stroke risk in CKD population Warfarin off-target effects on
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationNew Options for Anticoagulation Reversal: A Practical Approach
New Options for Anticoagulation Reversal: A Practical Approach Hyung Wook Park Chonnam National University Hospital, Gwangju, Korea 4 NOACs Prevention of TE No. of events (%/yr..) NOAC Warfarin HR 95%
More informationAndexanet alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding
Andexanet alfa in Factor Xa Inhibitor-Associated Acute Major Bleeding Stuart J. Connolly, M.D., Truman J. Milling, Jr., M.D., John W. Eikelboom, M.D., C. Michael Gibson, M.D., John T. Curnutte, M.D., Ph.D.,
More information